Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia.
| Autor: | Yoest JM; Department of Pathology, Case Western Reserve University, Cleveland, OH, United States., Shirai CL; Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, United States., Duncavage EJ; Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, United States. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in cell and developmental biology [Front Cell Dev Biol] 2020 May 08; Vol. 8, pp. 249. Date of Electronic Publication: 2020 May 08 (Print Publication: 2020). |
| DOI: | 10.3389/fcell.2020.00249 |
| Abstrakt: | Next generation sequencing (NGS) methods have allowed for unprecedented genomic characterization of acute myeloid leukemia (AML) over the last several years. Further advances in NGS-based methods including error correction using unique molecular identifiers (UMIs) have more recently enabled the use of NGS-based measurable residual disease (MRD) detection. This review focuses on the use of NGS-based MRD detection in AML, including basic methodologies and clinical applications. (Copyright © 2020 Yoest, Shirai and Duncavage.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|